MarketPulse

breast cancer drug

3 articles
The Motley FoolThe Motley Fool··Eric Volkman

Celcuity Surges on Bullish Cancer Drug Outlook as Analyst Initiates Coverage

Celcuity rises 4% after Citizens initiates 'market outperform' coverage with $150 price target, citing gedatolisib's breast cancer approval potential within two months and multi-indication opportunity.
CELCFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Celcuity With $170M Stake as Stock Soars 1,040%

Deerfield Management increased its Celcuity stake by $80.6M in Q4, bringing total position to $170.95M. Stock surged 1,040% amid FDA review of breast cancer drug gedatolisib.
CELCFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

Roche's Breast Cancer Drug Falls Short in Pivotal Trial, Stock Drops 5%

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.
LLYNVORHHBYclinical trial failurePhase 3 trial